sv-br-1-gm
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 16, 2018 (NCT03328026)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07199413 | Phase 1 | Mar 1, 2026 | Medical College of Wisconsin |
| NCT06072612 | Phase 3 | Oct 20, 2023 | BriaCell Therapeutics Corporation |
| NCT04418219 | Phase 1/Phase 2 (Phase 2) | Jul 21, 2020 | Thomas Jefferson University |
| NCT03328026 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2018 | BriaCell Therapeutics Corporation, Cancer Insight, LLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corporation | For profit | 2 | 2 | 2 | 2018 |
| Cancer Insight, LLC | For profit | 1 | 0 | 1 | 2018 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1